Priorities for efficacy trials of gender-affirming hormone therapy with estrogen: collaborative design and results of a community survey

Shira Grock; Jane Weinreb; Kristen C Williams; Amy Weimer; Sarah Fadich; Reema Patel; Atara Geft; Stanley Korenman

doi:10.1007/s42000-024-00532-3

Priorities for efficacy trials of gender-affirming hormone therapy with estrogen: collaborative design and results of a community survey

Hormones (Athens). 2024 Feb 5. doi: 10.1007/s42000-024-00532-3. Online ahead of print.

Authors

Shira Grock^{1

2

3}, Jane Weinreb^{4

5}, Kristen C Williams⁶, Amy Weimer^{4

6

7}, Sarah Fadich⁴, Reema Patel^{8

4

6}, Atara Geft^{5

9}, Stanley Korenman^{8

4

6}

Affiliations

¹ Division of Endocrinology, Diabetes and Metabolism, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA. sgrock@mednet.ucla.edu.
² University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA. sgrock@mednet.ucla.edu.
³ UCLA Gender Health Program, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA. sgrock@mednet.ucla.edu.
⁴ University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
⁵ Division of Endocrinology, Diabetes and Metabolism, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 90073, USA.
⁶ UCLA Gender Health Program, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
⁷ Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
⁸ Division of Endocrinology, Diabetes and Metabolism, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
⁹ Division of General Internal Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 90073, USA.

PMID: 38311658
DOI: 10.1007/s42000-024-00532-3

Abstract

Purpose: Treatment guidelines for gender-affirming hormone therapy with estrogen (GAHT-E) recommend specific dosing regimens based on limited data. Well-controlled efficacy trials are essential to tailoring treatment to patient goals as the guidelines recommend. The goal of this study was to take a foundational step toward designing community-centered effectiveness trials for gender-diverse individuals seeking GAHT-E.

Methods: Our team developed a cross-sectional survey based on broad clinical experience and consultation with our community advisory board. The survey included 60 items covering demographics, transition history, goals and priorities for treatment, indicators of treatment success, sexual function goals, and future research priorities. The survey was distributed during the summer of 2021, primarily through social networks designed for gender-expansive individuals seeking treatment with estrogen.

Results: A total of 1270 individuals completed the survey. Overall treatment goals most frequently rated "extremely important" or "very important" were the following: (1) improved satisfaction with life (81%), (2) appearing more feminine (80%), (3) appearing less masculine (77%), (4) improved mental health (76%), and (5) being seen as your true gender by others (75%). The three body characteristics most frequently rated "highest priority" or "high priority" among changes were the following: (1) facial hair (85%), (2) breast shape or size (84%), and (3) body shape (80%). The highest-rated research priority was comparing feminization with different routes of estrogen administration.

Conclusion: The goals and experiences of individuals seeking GAHT-E are diverse. Future clinical trials of GAHT-E should be grounded in the needs and priorities of community stakeholders.

Keywords: Estrogen; GAHT; HRT; Research design; Transgender.